Nurix Therapeutics Announces $55 Million Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Berenberg Reiterates Buy Rating on Nurix (NRIX) Following Earnings, Offers Comments on NX-2127
July 8, 2022 10:43 AM EDTBerenberg analyst Zhiqiang Shu reiterated a Buy rating and $48.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Lead program NX-2127 has moved to a Phase 1b dose expansion study. Reported at the R&D day on May 26, NX-2127, a BTK inhibitor with iMiD activity, led to deep and sustained degradation of BTK. Recall, among 13... More
